TransMedics Group
General Information | |
Business: |
We are a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. |
Industry: | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
Employees: | 92 |
Founded: | 1998 |
Contact Information | |
Address | 200 Minuteman Road. Andover, MA 01810, US |
Phone Number | (978) 552-0900 |
Web Address | http://www.transmedics.com |
View Prospectus: | TransMedics Group |
Financial Information | |
Market Cap | $323.8mil |
Revenues | $13.0 mil (last 12 months) |
Net Income | $-23.8 mil (last 12 months) |
IPO Profile | |
Symbol | TMDX |
Exchange | NASDAQ |
Shares (millions): | 5.7 |
Price range | $16.00 - $16.00 |
Est. $ Volume | $91.0 mil |
Manager / Joint Managers | Morgan Stanley/ J.P. Morgan |
CO-Managers | Cowen and Company/ Canaccord Genuity |
Expected To Trade: | 5/2/2019 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |